Patient no. | Sex | Age, yr | Diagnosis | No. of prev. episodes | Present episode duration | No. prev. AD trials | Prev. ECT | No. aug. trials | Mirtazapine dose, mg/d | Treatment duration | Concomitant medication | CGI-1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | F | 44 | MDD, fibromyalgia | 3 | 10 yr | 12 | Yes | 2 | 15 | 3 yr | Amitriptyline, clonazepam | 3 |
2 | F | 20 | MDD | 1 | 3 mo | 8 | No | 1 | 45 | 7 wk | Citalopram, clonazepam, lithium, lorazepam, nortriptyline, quetiapine | 5* |
3 | F | 50 | MDD | Many | 11 yr | 13 | Yes | 7 | 30 | 8 mo | Clonazepam, methotrimeprazine, perphenazine | 4 |
4 | M | 48 | MDD | 1 | 3 yr | 6 | No | 1 | 30 | 3 mo | None | 4 |
5 | F | 45 | MDD | Many | 4 yr | 9 | Yes | 1 | 60 | 18 wk | Ativan, bupropion, oxazepam, risperidone, trazadone | 4 |
6 | F | 57 | MDD, fibromyalgia | 1 | 3 mo | 2 | No | 0 | 15 | 3 yr | Clonazepam, methotrimeprazine, temazepam | 3 |
7 | F | 45 | MDD, OCD | 7 | 1 yr | 12 | No | 0 | 60 | 5 mo | Divalproex sodium, loxapine, olanzapine, | 4 |
8 | F | 81 | MDD | Many | 4 yr | 5 | No | 0 | 30 | 14 mo | None | 2 |
9 | M | 35 | MDD, PD, GAD, OCD, social phobia, hiatus hernia | 1 | 5 yr | 6 | No | 5 | 30 | 2 mo | Clonazepam, zopiclone | 4 |
10 | F | 66 | MDD | 3 | 10 mo | 7 | No | 0 | 15 | 6 mo | Lorazepam, zopiclone | 5 |
11 | F | 27 | MDD, eating disorder | 2 | 4 yr | 3 | Yes | 1 | 45 | 1 mo | Lorazepam, clonazepam, zopiclone | 2 |
12 | F | 71 | MDD, substance dependence disorder | 5 | 2 yr | 9 | No | 5 | 45 | 2 wk | Zopiclone | 6* |
13 | F | 36 | MDD, PTSD, social anxiety | 3 | 4 mo | 6 | No | 0 | 45 | 1 year | Ativan, oxazepam | 3 |
14 | M | 27 | MDD | 1 | 10 yr | 12 | Yes | 2 | 45 | 2 mo | Zopiclone | 4 |
15 | M | 43 | MDD, hypothyroidism | 4 | 18 mo | 9 | No | 2 | 30 | 10 wk | Levothyroxine | 4 |
16 | F | 35 | MDD | 20 | 3 mo | 2 | No | 0 | 30 | 1 mo | Clonazepam, paroxetine | 6* |
17 | F | 50 | MDD, hiatus hernia | 3 | 14 mo | 6 | No | 0 | 60 | 6 wk | Methotrimeprazine, zopiclone | 4 |
18 | M | 72 | MDD | 3 | 15 mo | 2 | No | 0 | 45 | 6 wk | Paroxetine, zopiclone | 5* |
19 | F | 46 | MDD with psychotic features, sleep apnea | 4 | 4 mo | 4 | No | 4 | 30 | 8 mo | Liothyronine, lorazepam | 3 |
20 | M | 34 | MDD | 4 | 11 mo | 4 | No | 0 | 30 | 3 mo | None | 2 |
21 | M | 47 | MDD, attentiondeficit | 4 | 4 yr | 7 | Yes | 1 | 30 | 1 wk | Clonazepam, oxazepam, zopiclone | 5* |
22 | F | 31 | MDD | 6 | 5 yr | 11 | Yes | 2 | 90 | 2 mo | None | 2 |
23 | F | 20 | MDD with psychotic features, bulimia nervosa | 3 | 16 mo | 8 | Yes | 1 | 30 | 15 mo | Lorazepam, loxapine, zopiclone | 3 |
24 | F | 39 | MDD, GAD, PD | 7 | 2 mo | 9 | No | 1 | 30 | 2 mo | Clonazepam, zopiclone | 4 |
Mean | — | — | — | 6.1 | 3 yr | 7 | — | 1.5 | 38 | 7 mo | — |
Note: prev. = previous; AD = antidepressant; ECT = electroconvulsive therapy; aug. = augmented; CGI-I = Clinical Global Impressions-Improvement Scale; MDD = major depressive disorder; PD = panic disorder; GAD = generalized anxiety disorder; OCD = obsessive–compulsive disorder; PTSD = post-traumatic stress disorder.
↵* Mirtazapine was discontinued because of adverse effects.